ERS 2020 — Real-world efficacy of benralizumab in severe eosinophilic asthma


  • Pavankumar Kamat
  • Conference Reports
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Preliminary findings of a real-world study showed that benralizumab significantly reduced exacerbation rates in patients with severe eosinophilic asthma (SEA), including those with chronic rhinosinusitis with nasal polyps (CRwNP). 

Why this matters

  • Although the safety and efficacy of benralizumab have been established in phase 3 trials, its real-world data are limited.

Study design

  • Interim analysis (n=61) of the multicentre retrospective ANANKE study which evaluates the clinical characteristics and asthma exacerbations in patients with SEA receiving 12 weeks of benralizumab treatment.
  • The median follow-up duration was 9.3 (interquartile range, 6.1-11.7) months. 
  • Annualized exacerbation rates (AER) were assessed before and after the first injection of benralizumab (index date). 
  • Funding: AstraZeneca.

Key results

  • 34.4% of the patients had CRwNP in the past year.
  • The AER was 4.98 for any exacerbation and 1.25 for severe exacerbations during the year before the index date.
  • At follow-up, the AER decreased to 0.38 for any exacerbation (reduction of 92.4%) and 0.08 for severe exacerbations (reduction of 93.6%).

Limitations

  • The study is ongoing.
  • Retrospective design.